Fibrinogen-Coated Polyelectrolyte Microcapsules for Targeted Clot Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current targeted delivery technologies for intravenously administered clot regulating drugs are ineffective in treating critical conditions due to systemic administration, leading to side effects and inhibitor interactions, and require external resources or take days to weeks to deliver the drug payload, failing to leverage existing biochemical and biomechanical pathways for rapid targeting.
Innovation Solution
Development of polymer-protein microcapsules with a biodegradable polyelectrolyte shell, a polysaccharide core, and a fibrinogen coating that rupture under platelet contraction to deliver drugs like Factor VIII, Factor VII, or tissue plasminogen activator directly to clot sites, avoiding systemic side effects and inhibitor interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If targeted delivery technologies are used for intravenously administered clot regulating drugs, then drug delivery to clot sites is improved, but the system requires external resources or takes days to weeks to deliver the drug payload
Solution Approach 1:
The microcapsules utilize the body's own biochemical and biomechanical pathways (fibrin network formation and platelet contraction) to achieve targeting and drug release, eliminating the need for external resources such as magnets or lasers while delivering drugs rapidly to clot sites
2Productivity
If clot regulating drugs are administered systemically, then drug delivery to clot sites is achieved, but side effects and inhibitor interactions occur
Solution Approach 1:
The microcapsules are designed with a fibrinogen coating that enables them to integrate into the fibrin network specifically at clot sites, allowing localized drug delivery rather than systemic distribution, thereby achieving therapeutic effects at the target site while avoiding side effects and inhibitor interactions in other parts of the body
Solution Approach 2:
The fibrinogen coating acts as an intermediary that enables the microcapsules to specifically interact with the fibrin network at clot sites, facilitating targeted drug delivery while preventing systemic distribution and associated harmful effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microcapsules achieve targeted and rapid delivery of clot regulating drugs, reducing side effects and inhibitor interactions, and effectively treating conditions such as hemophilia A and B by releasing the drug only at the site of clot formation, thereby enhancing treatment efficacy and reducing bleeding or clotting duration.
Implementation Method 1
microcapsules with a biodegradable polyelectrolyte shell, a polysaccharide core, and a fibrinogen coating that rupture under platelet contraction to deliver drugs
Implementation Method 2
particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers
Data Source
AI summary
This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.